nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—Vulvovaginal candidiasis—Riluzole—amyotrophic lateral sclerosis	0.0526	0.084	CcSEcCtD
Canagliflozin—Vulvovaginal mycotic infection—Riluzole—amyotrophic lateral sclerosis	0.0506	0.0808	CcSEcCtD
Canagliflozin—Micturition urgency—Riluzole—amyotrophic lateral sclerosis	0.0488	0.0778	CcSEcCtD
Canagliflozin—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.0298	0.0476	CcSEcCtD
Canagliflozin—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.0231	0.0368	CcSEcCtD
Canagliflozin—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.0229	0.0365	CcSEcCtD
Canagliflozin—Thirst—Riluzole—amyotrophic lateral sclerosis	0.0211	0.0337	CcSEcCtD
Canagliflozin—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.0187	0.0298	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.0183	0.0293	CcSEcCtD
Canagliflozin—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.0182	0.029	CcSEcCtD
Canagliflozin—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.017	0.0272	CcSEcCtD
Canagliflozin—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.016	0.0256	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.0158	0.0253	CcSEcCtD
Canagliflozin—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.015	0.024	CcSEcCtD
Canagliflozin—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.0137	0.0219	CcSEcCtD
Canagliflozin—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.0136	0.0217	CcSEcCtD
Canagliflozin—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.0126	0.0201	CcSEcCtD
Canagliflozin—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.0121	0.0193	CcSEcCtD
Canagliflozin—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.0111	0.0176	CcSEcCtD
Canagliflozin—Syncope—Riluzole—amyotrophic lateral sclerosis	0.0108	0.0173	CcSEcCtD
Canagliflozin—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.0106	0.017	CcSEcCtD
Canagliflozin—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.0105	0.0167	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.0102	0.0163	CcSEcCtD
Canagliflozin—SLC5A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.0101	0.027	CbGpPWpGaD
Canagliflozin—SLC5A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.0101	0.027	CbGpPWpGaD
Canagliflozin—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0161	CcSEcCtD
Canagliflozin—SLC5A2—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00993	0.0266	CbGpPWpGaD
Canagliflozin—SLC5A1—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00993	0.0266	CbGpPWpGaD
Canagliflozin—Infection—Riluzole—amyotrophic lateral sclerosis	0.00981	0.0156	CcSEcCtD
Canagliflozin—Shock—Riluzole—amyotrophic lateral sclerosis	0.00971	0.0155	CcSEcCtD
Canagliflozin—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00968	0.0154	CcSEcCtD
Canagliflozin—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00959	0.0153	CcSEcCtD
Canagliflozin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.00923	0.0247	CbGpPWpGaD
Canagliflozin—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00922	0.0147	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00852	0.0136	CcSEcCtD
Canagliflozin—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00851	0.0136	CcSEcCtD
Canagliflozin—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00844	0.0135	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00807	0.0129	CcSEcCtD
Canagliflozin—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00784	0.0125	CcSEcCtD
Canagliflozin—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.0078	0.0125	CcSEcCtD
Canagliflozin—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00727	0.0116	CcSEcCtD
Canagliflozin—SLC5A1—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00727	0.0195	CbGpPWpGaD
Canagliflozin—SLC5A2—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00727	0.0195	CbGpPWpGaD
Canagliflozin—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00708	0.0113	CcSEcCtD
Canagliflozin—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00698	0.0111	CcSEcCtD
Canagliflozin—UGT2B4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00663	0.0178	CbGpPWpGaD
Canagliflozin—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00653	0.0104	CcSEcCtD
Canagliflozin—Rash—Riluzole—amyotrophic lateral sclerosis	0.00622	0.00993	CcSEcCtD
Canagliflozin—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00622	0.00992	CcSEcCtD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.00604	0.0162	CbGpPWpGaD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.00604	0.0162	CbGpPWpGaD
Canagliflozin—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00586	0.00936	CcSEcCtD
Canagliflozin—SLC5A1—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.0056	0.015	CbGpPWpGaD
Canagliflozin—SLC5A2—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.0056	0.015	CbGpPWpGaD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.00514	0.0138	CbGpPWpGaD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.00514	0.0138	CbGpPWpGaD
Canagliflozin—UGT2B4—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.00507	0.0136	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.00477	0.0128	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.00477	0.0128	CbGpPWpGaD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.00458	0.0123	CbGpPWpGaD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.00458	0.0123	CbGpPWpGaD
Canagliflozin—SLC5A1—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.00438	0.0117	CbGpPWpGaD
Canagliflozin—SLC5A2—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.00438	0.0117	CbGpPWpGaD
Canagliflozin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.00434	0.0116	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TPK1—amyotrophic lateral sclerosis	0.00352	0.00942	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TPK1—amyotrophic lateral sclerosis	0.00352	0.00942	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.00307	0.00823	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.00307	0.00823	CbGpPWpGaD
Canagliflozin—ALB—HDL-mediated lipid transport—APOE—amyotrophic lateral sclerosis	0.00306	0.0082	CbGpPWpGaD
Canagliflozin—UGT2B4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.00297	0.00795	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00295	0.00789	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00295	0.00789	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00295	0.00789	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00295	0.00789	CbGpPWpGaD
Canagliflozin—UGT2B4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.00293	0.00784	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00284	0.0076	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—VTA1—amyotrophic lateral sclerosis	0.00281	0.00753	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—VTA1—amyotrophic lateral sclerosis	0.00281	0.00753	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00277	0.00742	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00269	0.00722	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00269	0.00722	CbGpPWpGaD
Canagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.00267	0.00716	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.00261	0.007	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.00261	0.007	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.00261	0.007	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.00261	0.007	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.0025	0.00671	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.0025	0.00671	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—TUBA4A—amyotrophic lateral sclerosis	0.0025	0.00669	CbGpPWpGaD
Canagliflozin—UGT1A9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00245	0.00658	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—TUBA4A—amyotrophic lateral sclerosis	0.00238	0.00637	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.00235	0.00631	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—FIG4—amyotrophic lateral sclerosis	0.00235	0.00631	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.00233	0.00624	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.00233	0.00624	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00227	0.00609	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00227	0.00609	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—PFN1—amyotrophic lateral sclerosis	0.00225	0.00602	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	0.00223	0.00597	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—PFN1—amyotrophic lateral sclerosis	0.00214	0.00574	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CHMP2B—amyotrophic lateral sclerosis	0.00213	0.00571	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CHMP2B—amyotrophic lateral sclerosis	0.00213	0.00571	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—DAO—amyotrophic lateral sclerosis	0.00213	0.0057	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—DAO—amyotrophic lateral sclerosis	0.00213	0.0057	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00208	0.00557	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00208	0.00556	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00203	0.00543	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00193	0.00518	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PLB1—amyotrophic lateral sclerosis	0.00193	0.00516	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PLB1—amyotrophic lateral sclerosis	0.00193	0.00516	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.00189	0.00506	CbGpPWpGaD
Canagliflozin—UGT1A9—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.00188	0.00503	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—FIG4—amyotrophic lateral sclerosis	0.00182	0.00487	CbGpPWpGaD
Canagliflozin—ALB—Lipoprotein metabolism—APOE—amyotrophic lateral sclerosis	0.00176	0.00471	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.00173	0.00463	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—VCP—amyotrophic lateral sclerosis	0.00172	0.0046	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—VCP—amyotrophic lateral sclerosis	0.00172	0.0046	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—DAO—amyotrophic lateral sclerosis	0.00164	0.0044	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PLB1—amyotrophic lateral sclerosis	0.00161	0.00432	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PLB1—amyotrophic lateral sclerosis	0.00161	0.00432	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.00161	0.0043	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.0016	0.00429	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.00156	0.00418	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—SOD1—amyotrophic lateral sclerosis	0.00156	0.00417	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.00151	0.00405	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GSR—amyotrophic lateral sclerosis	0.00149	0.00399	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—GSR—amyotrophic lateral sclerosis	0.00149	0.00399	CbGpPWpGaD
Canagliflozin—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—amyotrophic lateral sclerosis	0.00137	0.00367	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.00134	0.00358	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.00133	0.00356	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—SOD1—amyotrophic lateral sclerosis	0.00127	0.0034	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.00125	0.00335	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PLB1—amyotrophic lateral sclerosis	0.00125	0.00334	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CST3—amyotrophic lateral sclerosis	0.00123	0.0033	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CST3—amyotrophic lateral sclerosis	0.00123	0.0033	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CHAT—amyotrophic lateral sclerosis	0.00122	0.00328	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CHAT—amyotrophic lateral sclerosis	0.00122	0.00328	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.00122	0.00327	CbGpPWpGaD
Canagliflozin—ALB—Lipid and lipoprotein metabolism—APOE—amyotrophic lateral sclerosis	0.00117	0.00313	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GSR—amyotrophic lateral sclerosis	0.00115	0.00308	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—APOE—amyotrophic lateral sclerosis	0.00115	0.00308	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—TUBA4A—amyotrophic lateral sclerosis	0.00111	0.00297	CbGpPWpGaD
Canagliflozin—UGT1A9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.0011	0.00294	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.00109	0.00292	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—SOD1—amyotrophic lateral sclerosis	0.00109	0.00291	CbGpPWpGaD
Canagliflozin—UGT1A9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.00108	0.0029	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CASP9—amyotrophic lateral sclerosis	0.00107	0.00287	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.00104	0.00277	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—SOD1—amyotrophic lateral sclerosis	0.00104	0.00277	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	0.00101	0.0027	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PFN1—amyotrophic lateral sclerosis	0.000997	0.00267	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000989	0.00265	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000944	0.00253	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000905	0.00242	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000904	0.00242	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CASP9—amyotrophic lateral sclerosis	0.000896	0.0024	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CASP9—amyotrophic lateral sclerosis	0.000896	0.0024	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CD40LG—amyotrophic lateral sclerosis	0.000863	0.00231	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000856	0.00229	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000842	0.00225	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000842	0.00225	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000841	0.00225	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.000824	0.00221	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000791	0.00212	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000785	0.0021	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00077	0.00206	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000769	0.00206	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—ERBB4—amyotrophic lateral sclerosis	0.000767	0.00206	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—ERBB4—amyotrophic lateral sclerosis	0.000767	0.00206	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—C3—amyotrophic lateral sclerosis	0.000762	0.00204	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.00075	0.00201	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000728	0.00195	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000728	0.00195	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000728	0.00195	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000716	0.00192	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000713	0.00191	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000694	0.00186	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000685	0.00184	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000685	0.00183	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000673	0.0018	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—IGF1—amyotrophic lateral sclerosis	0.000663	0.00178	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000657	0.00176	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000657	0.00176	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000649	0.00174	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—amyotrophic lateral sclerosis	0.000631	0.00169	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000625	0.00167	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—DAO—amyotrophic lateral sclerosis	0.000608	0.00163	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000604	0.00162	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000604	0.00162	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—APOE—amyotrophic lateral sclerosis	0.000593	0.00159	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—APOE—amyotrophic lateral sclerosis	0.000593	0.00159	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.000571	0.00153	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000542	0.00145	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000531	0.00142	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000529	0.00142	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000514	0.00138	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	0.000509	0.00136	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000507	0.00136	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—APOE—amyotrophic lateral sclerosis	0.000497	0.00133	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—APOE—amyotrophic lateral sclerosis	0.000497	0.00133	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	0.000482	0.00129	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000466	0.00125	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000461	0.00124	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000459	0.00123	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	0.000452	0.00121	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000446	0.00119	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	0.000442	0.00119	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000441	0.00118	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000441	0.00118	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—VEGFA—amyotrophic lateral sclerosis	0.000433	0.00116	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	0.000432	0.00116	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000426	0.00114	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSR—amyotrophic lateral sclerosis	0.000426	0.00114	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—amyotrophic lateral sclerosis	0.000412	0.0011	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000411	0.0011	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTGS2—amyotrophic lateral sclerosis	0.000407	0.00109	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTGS2—amyotrophic lateral sclerosis	0.000407	0.00109	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000403	0.00108	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000403	0.00108	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000391	0.00105	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000391	0.00105	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000388	0.00104	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000386	0.00103	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000386	0.00103	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—APOE—amyotrophic lateral sclerosis	0.000384	0.00103	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	0.000383	0.00103	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TP53—amyotrophic lateral sclerosis	0.000382	0.00102	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000375	0.001	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000353	0.000946	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000352	0.000944	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000349	0.000936	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000348	0.000933	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000342	0.000917	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000342	0.000917	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000341	0.000912	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000341	0.000912	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000328	0.000879	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000319	0.000854	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—DAO—amyotrophic lateral sclerosis	0.000319	0.000853	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.00031	0.000832	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000309	0.000827	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000306	0.00082	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000305	0.000817	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	0.000294	0.000788	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000289	0.000776	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	0.000279	0.000748	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000263	0.000704	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.000248	0.000666	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000241	0.000647	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	0.00024	0.000643	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000238	0.000637	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000238	0.000637	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000223	0.000597	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000223	0.000597	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSR—amyotrophic lateral sclerosis	0.000223	0.000597	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	0.000218	0.000585	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000218	0.000583	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000212	0.000567	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000203	0.000544	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000202	0.000542	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	0.000195	0.000523	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	0.000192	0.000514	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	0.00019	0.000509	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000189	0.000507	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000188	0.000503	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000183	0.00049	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000173	0.000462	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	0.000172	0.000461	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000167	0.000447	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	0.00016	0.00043	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IGF1—amyotrophic lateral sclerosis	0.000152	0.000406	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000143	0.000383	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—APOE—amyotrophic lateral sclerosis	0.000142	0.00038	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	0.00013	0.000349	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	0.00012	0.000322	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	0.000114	0.000306	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—amyotrophic lateral sclerosis	9.9e-05	0.000265	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	9.88e-05	0.000265	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.83e-05	0.000263	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.73e-05	0.000261	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.04e-05	0.000242	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.62e-05	0.000231	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.92e-05	0.000212	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—amyotrophic lateral sclerosis	7.48e-05	0.0002	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOE—amyotrophic lateral sclerosis	7.44e-05	0.000199	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	6.51e-05	0.000175	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.31e-05	0.000142	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.09e-05	0.000136	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.88e-05	0.000131	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.46e-05	0.00012	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	4.01e-05	0.000108	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.75e-05	7.37e-05	CbGpPWpGaD
